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Abstract
Background: Early intervention services for psychotic disorders optimally interlock strategies to deliver: (i) Early
Detection (ED) to shorten the time between onset of psychotic symptoms and effective treatment (i.e. Duration of
Untreated Psychosis, DUP); and (ii) comprehensive intervention during the subsequent 2 to 5 years. In the latter
category, are teams (‘First-episode Services’ or FES) that integrate several empirically supported treatments and
adapt their delivery to younger patients and caregivers. There is an urgent need to hasten access to established FES
in the U.S. Despite improved outcomes for those in treatment, these FES routinely engage patients a year or more
after psychosis onset. The Scandinavian TIPS study was able to effectively reduce DUP in a defined geographic
catchment. The guiding questions for this study are: can a U.S. adaptation of the TIPS approach to ED substantially
reduce DUP and improve outcomes beyond existing FES?
Methods/Design: The primary aim is to determine whether ED can reduce DUP in the US, as compared to usual
detection. ED will be implemented by one FES (STEP) based in southern Connecticut, and usual detection efforts
will continue at a comparable FES (PREP
R) serving the greater Boston metropolitan area. The secondary aim is to
determine whether DUP reduction can improve presentation, engagement and early outcomes in FES care. A
quasi-experimental design will compare the impact of ED on DUP at STEP compared to PREP
R over 3 successive
campaign years. The campaign will deploy 3 components that seek to transform pathways to care in 8 towns
surrounding STEP. Social marketing approaches will inform a public education campaign to enable rapid and
effective help-seeking behavior. Professional outreach and detailing to a wide variety of care providers, including
those in the healthcare, educational and judicial sectors, will facilitate rapid redirection of appropriate patients to
STEP. Finally, performance improvement measures within STEP will hasten engagement upon referral.
Discussion: STEP-ED will test an ED campaign adapted to heterogeneous U.S. pathways to care while also
improving our understanding of these pathways and their impact on early outcomes.
Trial registration: ClinicalTrials.gov: NCT02069925. Registered 20 February 2014.
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The promise of early detection
Psychotic disorders are a source of severe distress, dis-
ability and economic cost under usual systems of care.
The prototypic schizophrenia spectrum disorders affect
between 0.55% and 1% of people during their lives [1];
and typically manifest as a ‘first-episode’ of psychotic
symptoms in adolescence or early adulthood. This is an
especially formative period for social and vocational tra-
jectories and psychotic disorders are among the top 20
causes worldwide of years lived with disability (YLD), ex-
ceeding epilepsy, ischemic heart disease and Alzheimer’s
disease in their impact amongst the chronically ill [2].
With routine care, less than one-fifth of patients achieve
full recovery after a first episode of psychosis [3] and less
than one-third achieve minimal age-appropriate employ-
ment or education [4]. Chronic psychotic disorders, while
relatively less prevalent, lead annual U.S. expenditures on
mental illnesses, with $22.7 billion in direct healthcare
costs, and $32.4 billion in indirect costs stemming from
unemployment, reduced workplace productivity, prema-
ture mortality from suicide, and family caregiving [5].
Early intervention can significantly ameliorate the poor
outcomes of usual care. The first 2–5 years after psychosis
onset presage much of the eventual clinical and psycho-
social deterioration in schizophrenia spectrum disorders
[6] including one-third of completed suicides [7], relapse
and re-hospitalizations [8], violence [9] and neurocognitive
dysfunction [10]. This period also offers the opportunity
to modify several prognostic factors including substance
misuse, social isolation, negative symptoms and cognitive
dysfunction [11]. These factors can derail an already vul-
nerable period of emerging adulthood [12]. Relapses in the
first year or two after the first episode, and accumulated
duration of positive symptoms of psychosis in the first few
years of illness are associated with worse neurocognition
5–10 years later [13]. The hypothesis of a ‘critical period’,
wherein secondary prevention efforts 2–5y e a r sa f t e r
psychosis onset might disproportionately leverage long
term functional gains, [14] has stimulated a rich variety of
approaches to early intervention.
Early Intervention (EI) for psychotic disorders can be
conceptualized as including interlocking strategies to de-
liver: (i) Early Detection (ED) to shorten the time between
onset of psychotic symptoms and effective treatment (i.e.
Duration of Untreated Psychosis, DUP); and (ii) compre-
hensive intervention during the 2 to 5 years after identifi-
cation of a psychotic disorder [15]. Of particular promise,
in the latter category, are teams (henceforth ‘First-episode
Services’ or FES) that integrate several empirically sup-
ported treatments and adapt their delivery to younger
patients and their caregivers. FES have demonstrated im-
provements in symptoms, functioning and costs in a range
of healthcare systems [16,17]. The two collaborating FES
in this project (clinic for Specialized Treatment Early in
Psychosis, or STEP in New Haven and Prevention and
Recovery in Early Psychosis, or PREP
R in Boston) have
successfully applied comparable FES in similar settings
to deliver feasible, sustainable and effective care [18,19].
STEP recently completed the first U.S. randomized con-
trolled trial to determine the feasibility and effectiveness
of this public-sector based approach to FES [18]. This
trial has also collected detailed information on sources
of direct and indirect cost [20-22] that support inter-
national data on the health economic benefits of FES.
There is an urgent need to hasten access to FES in the
U.S. Despite improving outcomes for those in treatment,
STEP and PREP
R continue to admit patients long after
psychosis onset. For example, over half (51%) of all en-
trants to STEP over the past 6 years had endured a DUP
longer than 3 months with evidence of significant morbid-
ity on arrival to the service: about 10% of entrants had
already attempted suicide, 45% had a co-morbid substance
use disorder and 60% had dropped out of school or em-
ployment while 90% entered care after a behavioral crisis
requiring hospitalization [23]. The same proportion (50%)
had endured a similarly prolonged DUP over the past
5 years at PREP
R.
Early Detection has the potential to substantially re-
duce DUP and extend the impact of existing FES. The
largest experimental study of ED has been the TIPS
study. TIPS delivered a combination of public and tar-
geted education campaigns coupled with rapid availabil-
ity of FES in 2 healthcare sectors in Norway, whereas
two control sectors (in Norway and Denmark) delivered
comparable FES without the benefit of these efforts to
reduce DUP. This strategy more than halved DUP (from
a median of 15 to 4.5 weeks) [24] at the ED sites. This
DUP reduction was tied to markedly reduced distress and
disability at clinical presentation, including reduced posi-
tive and negative symptoms of psychosis [24] and suicidal
behavior [25]; persistently improved negative symptoms at
5 years [26] and resulted in twice the rate of recovery (31
vs. 15%) at 10 years [27]. Notably, when the information
campaign was interrupted due to lack of continued fund-
ing, this resulted in a decay of the DUP toward the control
levels followed by attendant worsening in outcomes [28].
This validated a causal role for DUP in affecting outcomes
rather than functioning solely as a marker of poor progno-
sis subgroups [29]. Although one other study in Singapore
used a similarly broad, multifocal campaign to reduce
DUP and improve pathways to care, [30] other less
comprehensive attempts have failed to reduce DUP [31],
demonstrating the challenge of replicating the promising
findings from TIPS.
Several factors argue for careful study rather than
straightforward application of the TIPS approach to U.S.
settings. Pathways to specialty care in the U.S. are diverse,
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pact of other efforts toward early detection. Also, the an-
ticipated but unclear changes in U.S. pathways over time
(e.g. with ongoing reforms in access to health insurance
[22]) make it vital to test any ED strategy against a control
setting to disentangle the effects of an ED campaign from
secular changes in the U.S. healthcare environment. Fi-
nally, FES care is a rarity in most U.S. settings and can re-
duce DUP in a region simply by its presence. Controlling
for this effect across 2 established FES can a) help disen-
tangle the impact on DUP of a distinct ED campaign and,
b) if the ED campaign is successful, clarify the added value
of optimizing timing (ED) over already existing efforts to
improve the quality of early treatment (i.e. FES).
Contextualizing early detection within pathways to care
Our attempt to reduce DUP in the complex U.S. health-
care environment uses a model (Figure 1) that (a) incor-
porates local knowledge and uncertainty of the size and
determinants of various sources of delay and (b) the
pathways to care that reveal potentially malleable nodes
on which to prioritize efforts. We prefer to categorize the
determinants of DUP as including a ‘demand’ side (e.g. de-
lays in effective help-seeking resulting from factors includ-
ing delays in illness identification and delayed attempts to
access healthcare by patients and caregivers) [32] and a
‘supply’ side (delays by professionals in initiating treatment
that include delays in diagnosing and initiating or referring
to appropriate treatment). Given the variability of impact
of sources of delay across various U.S. settings, our
approach is agnostic on whether to prioritize demand or
supply side interventions. We begin with the premise that
deploying interventions targeting these two domains of
DUP with already demonstrated success (in the TIPS
project) provides an empirically tractable basis for the
main goal of DUP reduction while also allowing for vital
information to be collected on determinants of DUP
within the context of local pathways to care.
Pathways to care can be defined as “the sequence of
contacts with individuals and organizations prompted by
the distressed person’s efforts, and those of his or her
significant others, to seek help as well as the help that is
supplied in response to these efforts [33]”. This high-
lights the interleaved behaviors of help-seeking by pa-
tients and families on the one hand, and the response of
professionals and agencies on the other in generating a
particular patient’s pathway into treatment. There is con-
siderable information on a diverse set of barriers relevant
to U.S. pathways, but the lack of consensus on measures
and the multiplicity of factors limits straightforward appli-
cation of available measures to a particular geographic
area. Fortunately, STEP has collected relevant information
over 6 years of recruiting from the local catchment that
has included more than 600 formal inquiries and multiple
informal consultations to families, clinics and area non-
healthcare settings (e.g. churches, schools, mosques). This
has allowed us to populate a heuristic model. While not
exhaustive, it integrates salient elements of our local path-
way to care.
We integrate these ideas in a modified version of the in-
fluential Goldberg-Huxley model [34] (Figure 1) to under-
stand the interaction of both patient/caregiver factors and
system factors relevant to DUP. The choices for sampling,
ED implementation, measurement and analysis, described
in the succeeding sections, derive from this model. While
not exhaustive, the boxes correspond to the most com-
mon ‘levels’ or recognized sources of care in STEP’st a r g e t
catchment (8 towns). The model conceives of these levels
Figure 1 Heuristic model for DUP in STEP’s catchment.
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hastening access to STEP for some kinds of patients while
potentially delaying it for others. This phenomenon of fil-
tering, whereby different levels of care may influence
access in non-random ways, is exemplified by STEP’se x -
perience of rapid (short-DUP) referrals of agitated, pre-
dominantly male patients from acute settings on the one
hand, while also explaining a paradoxical finding reported
in other settings: prior connection to outpatient care may
actually delay entry to specialty FES [35]. Particular kinds
of patients may proceed through particular ‘levels’ of care
with unexpected speed or delay and this suggests the need
to target, measure and analyze sources of DUP within the
context of local pathways.
Pathways to care can be usefully conceptualized, from
the perspective of the patient or caregiver, across 4 princi-
pal events: the onset of psychotic symptoms, a recognition
of a need for care with related help-seeking behavior, an
encounter with a professional agency and finally, entry into
specialty first-episode care. Within our model, the sources
of delay are best illustrated by the example depicted by the
pathway taken by one patient (‘a’) to the STEP clinic and
depicted by the arrows in Figure 1:
VS suffered the onset of psychotic symptoms 4 months
before his mother decided to call the police after he
pushed her to the floor and threatened her with a
kitchen knife. The police officer found him to be
disheveled, loudly alleging that “[the neighbors are]
messing with my business” and that his mother “does
not believe me.” The officer had to threaten VS with
arrest to get him to agree to an evaluation in the local
emergency room. He arrived in the hospital upset and
refusing to cooperate with the psychiatric evaluation, at
one point requiring soft leather restraints and
involuntary intramuscular medication after he threw
his food tray at a staff member and attempted to run
away. After a brief hospitalization of four days during
which he agreed to take antipsychotic medications,
and follow-up with aftercare, he was discharged with a
referral to the STEP clinic. VS did not show for his
first appointment at STEP and when called at home
indicated he did not wish to seek further care. After 2
more involuntary hospitalizations under similar
circumstances and his mother’s insistence that he
return to STEP in order to be able to continue to
live at home, he arrived for his first outpatient
appointment, 8 months after the onset of psychotic
symptoms. Another month elapsed before VS agreed to
resume antipsychotic medication and engage with his
primary clinician in developing a treatment plan that
focused on his goals of returning to community college
and finding part-time employment. He remains
unwilling, six months later, to explicitly acknowledge
the role of a psychotic illness in his difficulties, but is
adherent to medications and working with a supported
employment specialist to develop his resume for
competitive employment.
The story illustrates several salient contributors to
DUP. The delayed recognition of the presence of an ill-
ness by the patient and his mother reflects a combin-
ation of factors including lack of awareness of the signs
of mental illness and of available resources, denial, and
fear of stigma - all of which delay effective help-seeking
behavior that could have preempted the behavioral crisis
and police intervention. The aversive experience of en-
tering and receiving care under duress likely reduced the
patient’s willingness to follow through on referrals to an
FES. Many other combinations of the various levels are
involved in the variety of pathways that contribute to the
‘demand’ and ‘supply’ components depicted in Figure 1.
It is important to note that the demand and supply con-
tributors to DUP often do not resolve in a linear fashion,
but can result from a dynamic interplay of events. For
example, a patient may enter an FES at the behest of a
parent, with effective interruption of the DUP long
before they can identify the presence of symptoms or
the need for professional care. This perspective informs
the pluralistic strategy of the campaign detailed below,
which envisions diverse ways to interrupt DUP that seek
to facilitate, but do not require, salutary changes in atti-
tudes, beliefs or stigma.
The STEP-ED campaign will target both the lack of
effective ‘demand’ for specialty care (dotted line) and ef-
fective ‘supply’ of such care (solid lines) in 3 principal
ways: (1) a public Education Campaign (PEC), (2) out-
reach to and academic detailing of professionals (PO) to
modify the filtering enacted at the various levels depicted
in the model and (3) implementing Rapid Access to STEP
(RAS) that will include a variety of performance improve-
ment tactics to reduce the time between referral and ad-
mission to STEP.
Aims and Hypotheses
This study seeks to test of the effectiveness of an early de-
tection campaign in a policy-relevant U.S. setting, where
relatively fragmented pathways to care magnify both the
challenges and the potential public health impact. The
presence of 2 similar, effective, geographically separated
but collaborative FES programs (STEP and PREP
R)p r e -
sented an excellent opportunity to conduct such a test
and thereby advance secondary prevention for psychotic
illnesses in the U.S.
The guiding questions for this study are: can a U.S.
adaptation of the TIPS approach to early detection sub-
stantially reduce DUP and improve outcomes beyond
existing FES?
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To determine whether early detection intervention can
reduce DUP in the US, as compared to usual detection.
Early detection (ED) will be implemented in one US com-
munity (New Haven, CT), and usual detection efforts will
continue in another (Boston, MA). DUP will be measured
at admission to the corresponding services (STEP &
PREP
R) in each community, over one year before and
throughout ED implementation. We hypothesize that
DUP will be reduced significantly in the early detection
site compared to the usual detection site.
The secondary aim is
To determine whether DUP reduction can augment the
outcomes of established FES. We will measure symp-
toms, functioning and engagement with treatment at
entry and over 1 year at each site. We hypothesize that
the shorter DUP engendered by the ED campaign at one
FES (STEP) will result in reduced distress and illness se-
verity at entry and better 1 year outcomes and engage-
ment at STEP vs. PREP
R.
Methods/Design
Design rationale
Any effort to test the impact of an early detection strategy
to reduce DUP and determine the subsequent impact on
early outcomes, must confront specific biases [36] that are
each addressed in the Procedures detailed below. First
however, the overall rationale for the quasi-experimental
design involving 2 sites is outlined:
Primary aim
Any test of a DUP reduction strategy in a community
has to consider 2 main sources of confounding. First,
unexpected changes in either direction for DUP may
occur over the life of this study (e.g. variation in health-
care access due to macroeconomic changes) that will
imperil inferences from the sole use of a historical con-
trol to determine the impact of ED on DUP. The parallel
control in this proposal (PREP
R) ameliorates this con-
cern by being carried out during the same period and
allowing for careful measurement (see below) of these
influences. In addition, the historical control design in
New Haven (pre- and post-ED) also allows us to con-
sider the effects of ED without the impact of unknown
sources of heterogeneity in DUP across sites. The sec-
ond source of confounding is preferential sampling from
the larger target sample of new onset cases. For example,
a correlation between ED and shorter DUP might merely
reflect strategic success at diverting short DUP cases to
STEP, while longer DUP cases remain untreated, or
treated elsewhere, in the community. This is addressed
by (a) our intensive media and targeted education cam-
paign to facilitate representative recruitment from across
the catchment and (b) the availability of a historical con-
trol at the STEP site, wherein DUP distributions available
for years before ED implementation will allow pre-post
comparisons to assess for differential skewing. Finally, (c)
DUP will also be measured at a major community mental
health center (the Hill Health Center, HHC, Connecticut)
in the catchment area of the ED intervention for one year
before and during the ED implementation. Specifically we
will measure DUP for those who are not successfully re-
ferred to STEP. Three possibilities will be considered for
this group: if DUP at HHC remains the same or falls, this
would reassure us that ED had no effect or a salutary ef-
fect on help-seeking, even if not to STEP; while if the
DUP rises for this group, it would raise concerns for
biased sampling as described above. Notably, such skewed
sampling did not occur in the TIPS project [37] and given
the similar catchment based design, and the reality that
few competing resources for early psychosis care are avail-
able in the STEP catchment, such skewing is unlikely to
occur in STEP-ED.
Secondary aim
Disentangling the additional benefit of DUP reduction on
the early outcomes of FES care would ideally be deter-
mined by randomized allocation of ED vs. no-ED within a
single sample that would all subsequently receive the same
FES care. This is fraught with logistical challenges. Any
effective public education campaign would be hard to iso-
late to only some members of a catchment. The next best
alternative is the quasi-experimental controlled design pro-
posed here, with careful assessment (see Measurement)
and statistical adjustment (see Analysis) for inevitable sam-
ple differences with equivalent FES care (STEP or PREP
R)
at two geographically separated sites. A residual bias is that
a correlation of DUP with better 1 year outcomes at the
ED site (i.e. STEP) does not rule out the possibility that
better (or worse) prognosis cases were easier to detect and
enter into FES early [38] increasing the chances of a Type
1 (or 2) error, respectively. For example, patients with
insidious-onset, deficit symptom ridden illnesses (with gen-
erally poorer prognoses) may be quietly psychotic for years
before coming to therapeutic attention whereas good prog-
nosis patients with sudden and visible positive symptom
related alterations in behavior may alert observers and
come to the attention of health providers and preferentially
enter STEP. Conversely, the acute, rapidly resolving psych-
otic disorders (with better prognoses) may be less likely to
be discovered by our early detection campaign than those
who are continuously symptomatic in the catchment [39].
Having a parallel control site with careful measurement of
diagnostic profiles and other prognostic factors at each site
(see Measurement) will allow us to limit the impact of this
bias. Also this will allow analysis for the possibility that
DUP is, for different subgroups, both a malleable mediator
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are less responsive to FES [40].
Additional biases related to patient refusal (e.g. longer
DUP patients tending to decline participation in the
TIPS study [41]) and unanticipated exclusions will also
be measured and adjusted for in the analysis.
Sampling
The early detection strategy (ED) will target all residents
of a designated geographic catchment contiguous with the
Connecticut Mental Health Center (CMHC) in which
STEP is located. This includes the 8 towns of Bethany,
Orange, Woodbridge, Hamden, New Haven, East Haven,
West Haven and North Haven, with a total population of
323,285 (Census, 2010) and for which we estimate an an-
nual incidence 40–70 cases of schizophrenia-spectrum
disorders. The catchment was chosen based on feasibility
of travel for care at STEP. The intensive approach to as-
certainment of new onset cases from across the catchment
will include public messaging and targeted outreach to all
major treatment centers. Also measurement of DUP will
be undertaken at one other major community mental
health center that draws from this catchment zone. At this
community ‘sentinel’ site, in addition to the usual out-
reach, clinical records will be reviewed on a regular basis
to determine the prognostic profile and DUP of patients
who were not successfully referred to STEP for initiation
of treatment. The control site, PREP
R is based in the
Jamaica Plains area of Boston and while it draws from a
much larger metropolitan population of more than 4 mil-
lion (Census 2010), the demographic and prognostic pro-
file of usual recruits over the past 5 years have been
broadly comparable to that of STEP (see section Choice of
Control site below).
The focus of early intervention after the onset of a
psychosis is to improve the outcomes of individuals with
schizophrenia-spectrum disorders. The reality, embraced
by all exemplar early intervention programs, is that an
accurate diagnosis is often difficult to make at the time
of symptom onset [42]. Thus a ‘first-episode’ psychosis
sample will necessarily include patients who will, on lon-
gitudinal follow-up, turn out to have less severe illnesses
such as major depression with psychotic features, brief
psychotic disorder or bipolar disorder (with psychotic
features). The study population is thus expected to be
diagnostically heterogeneous in the service of identify-
ing, with as much sensitivity as possible, those who are
likely to develop chronic psychotic illnesses.
We will thus use criteria that are simple to communicate
and apply, to minimize delays in determining eligibility:
Inclusion Criteria: 16–35 years old, must live within
catchment of interest (For PREP
R: greater Boston
metropolitan area; for STEP: 8 town catchment) and
must have had their first-episode of psychosis within
the past 3 years.
Exclusion Criteria: Established diagnosis of Affective
psychosis (i.e. non-ambiguous Bipolar d/o or MDD with
psychotic features) or Psychosis secondary to substance
use or a medical illness, unable to communicate in
English, eligible for DDS (Department of Developmental
Services), legally mandated to enter treatment, unable to
reliably determine DUP, unstable serious medical illness.
We will exclude from this study, those patients who
converted to psychosis while being followed and cared
for in prodromal clinics (i.e. DUP of 0), which exist at
both sites. We will also exclude those who have
previously received care at another FES.
Reasons for exclusion and patient refusal will be re-
corded for all referrals. DUP will be estimated for refusers
who are otherwise eligible, to gauge the impact of sam-
pling bias on the relationship between DUP reduction and
early outcomes.
Written informed consent for participation in the study
will be obtained from all adult participants. For those par-
ticipants under 18 years of age, written consent will be
obtained from a parent or legal guardian in addition to
written assent from the participant. All procedures are in
compliance with the Helsinki Declaration and have re-
ceived ethics approval from the Yale University Human
Investigation Committee (Protocol Number: 1310012846).
Intervention: the early detection campaign
Theory of the campaign
The STEP-ED campaign seeks to reduce all malleable
sources of delay that contribute to the duration of un-
treated psychosis (DUP). As noted above, we conceive of
two broad sources of delay. The first refers to the ‘Demand’
(identification of illness and initiation of help-seeking) for
care and the second covers events that refer to the ‘Supply’
of the needed care (correct identification of diagnosis and
referral to first-episode services).
To intervene on the Demand side, the campaign will
transmit messages to hasten identification (by the patient,
caregiver or friend) of a need for professional assistance
and enable effective help-seeking behavior. There is a con-
siderable body of literature with a number of models that
emphasize different approaches to inducing such changes
in health behavior. However, empirical testing of specific
interventions based on these models has been inconclu-
sive [43]. For example, there was no difference between
messaging based on the Theory of Reasoned Action and
general informational messaging in encouraging young
men to perform testicular self-examinations [44]. A test
of the influential Transtheoretical Model of Change,
found that interventions carefully matched to an indi-
vidual’s stage of change were actually less effective than
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Furthermore, these theories can be criticized for de-
contextualizing the process of acting to take care of
one’s health, treating individuals as ‘islands’ of cognitive
and deliberative processes. This reduced their face val-
idity for disorders that are marked by poor insight.
In contrast, the STEP-ED campaign will employ an
ecological approach. Demand-side events (such as identi-
fying that there is a problem) including internal cognitive
processes in a patient or family member, are expected to
routinely interact with Supply-side events, such as the re-
sponses of service providers and other helpers in the com-
munity. This ecological approach targets networks [46] of
potential first responders who determine patients’‘ path-
ways to care’ which do not solely or even substantially rely
on putative drivers of individual health behavior that have
been posited in extant models [43]. A modified Goldberg-
Huxley model of pathways to care (introduced in Context-
ualizing early detection within pathways to care) highlights
the interaction of patients/families with various care pro-
viders and introduces the concepts of ‘levels’ of care and
‘filters’ of care that is expanded in our approach beyond
traditional clinical settings to include community agencies
or non-clinical actors who are influential in determining
DUP. While ‘levels’ can be conceived of as the different
agencies that deliver different grades of expertise at differ-
ent stages and needs of the illness,‘filters’ refers to the ac-
tive role these agencies might play in differentially
modifying DUP for different sub-groups or patients or dif-
ferent presentations of illness/need.
While we assume that all of the actors in our local
pathways to care (see Figure 1) may, for different pa-
tients, play a causal role in DUP and are thus part of our
model, we do not presume to attribute weights to their
relative importance. Research in other systems of care that
have employed selective campaigns (e.g. focused only on
the Supply side by educating GPs) suggests that a broader
‘kitchen-sink’ [47] approach that is agnostic about, and
treats their relative weights as an empirical question (espe-
cially within the more fragmented US healthcare ecology)
is more likely to achieve DUP reduction. The STEP-ED
campaign, will therefore be pluralistic and implement
three interlinked areas relevant to DUP.
Components of the campaign
The first year of the study period will be used to develop
the campaign. The broad outline of the 3 components is
depicted in Table 1. While the theory and structure or
overall strategy of the campaign are described above; the
specific tactics, including messaging, choice and use of
channels of dissemination and real-time adaptations will
employ novel social marketing approaches. Specifically,
this will include development of a campaign brand image
and logo, the use of analytic tools (e.g. Google analytics) to
assess online traffic related to STEP-ED’s message disag-
gregated by target sub-populations (e.g. age, gender, town
of residence) with the ability to course correct the target-
ing of messages. While traditional ‘mass media’ channels
will also be deployed, the advantage of social media will be
exploited to achieve comparable and more youth appro-
priate mass circulation while retaining the ability to
personalize the message and have it amplified in a cost-
effective manner (e.g. sharing via peers on Facebook).
The campaign development process and final details
of all 3 components will be available in a forthcoming
paper, but the overall structure is summarized below:
Public Education Campaign (PEC) The target popula-
tion of the PEC is those individuals with early psychosis,
and their caregivers or friends, who are yet to make
contact with one of the levels of care. Messaging will be
developed to enable effective help-seeking by providing
specific, actionable, and persuasive messages on (1) how
to identify the signs and symptoms of psychosis; (2) how
to access professional evaluation and effective care at
STEP; and (3) the effectiveness of early treatment. While
some of the early message development will include
feedback from focus groups, real-time feedback and re-
finement will be a key feature, with the use of online tools
to track visits to social media and web sites. The channels
for the media campaign will include television, radio, bus
ads, a website, social media (e.g. Facebook, Twitter, &
YouTube), promotional items, and print materials for pro-
fessionals to share with at-risk youth and parents.
Professional Outreach and Detailing (POD) Profes-
sionals in the 8 levels posited to influence pathways to
care in our area (see Figure 1) will be targeted via inter-
personal outreach (face-to-face meetings, workshops,
and phone calls) and resource materials (print and web-
based) followed by a focus on careful detailing of key
referral sources identified during initial outreach. In keep-
ing with evidence from the limited literature on what ap-
pears to influence provider behavior [48,49] we will use
detailing as a way to both understand barriers and enable
actions that will successfully and quickly divert patients to
STEP for care. All materials will be designed to transmit a
uniform message consistent with the PEC. Multiple stake-
holders within each setting will be identified and an
appropriate plan for repeated contact or detailing will
be devised. For instance, the campaign targeting col-
leges in our catchment will include in-service sessions
for Counselors followed by regular visits to their clinics
to refresh the message and allow for consultation on po-
tential referrals. The PEC will also serve as a reminder
to professionals about the key points of the project and
remind them of their important role in referring pa-
tients to STEP.
Srihari et al. BMC Psychiatry 2014, 14:335 Page 7 of 14
http://www.biomedcentral.com/1471-244X/14/335Rapid Access to STEP (RAS) Seamless access to STEP
will be an important component of reducing supply side
contributors to DUP. Careful coordination will also be
maintained with the Connecticut-wide 24 hr warm line
(211) to route all potential early psychosis referrals to
STEP. All messages to the STEP line will be cleared within
24 hours. A structured telephone screening will establish
the presence of a new onset psychiatric illness within the
inclusion age range and a request for help from either the
adult patient or caregiver of a minor. If a potential pro-
dromal or psychotic illness is suspected, in-person evalu-
ation will be offered within one working day. This can
begin, if necessary, in the patient’s home, school or referral
setting (primary care clinic or psychiatrist office). For re-
ferrals in which the caregiver is seeking help in the face of
patient reluctance or a behavioral emergency, education
about available resources will be provided to the caregiver
(including how to access emergency services and local
parent and youth led consumer organizations) and on-
going support to problem solve and enable entry into care.
In all cases, repeated attempts to contact by phone and of-
fers to meet in the community will be made until explicit
refusal from the patient, to counter the common ambiva-
lence that can delay entry into care. When the patient
consents to care, caregivers will be invited to participate in
structured family education interventions (offered as a
routine part of STEP and PREP
R care) that we expect will
also facilitate the patients’ engagement into care.
Choice of control site
A significant strength of this design is the degree to which
the 2 sites can claim to draw from equivalent samples.
Relevant to this judgment are the similar cultures, recruit-
ment and treatment philosophies at the 2 FES (STEP, New
Haven and PREP
R, Boston) that have been active over an
equivalent period of time and exist within longstanding
academic collaborations with State mental health agencies.
Both clinics are located within diverse, urban settings
and have a history of recruiting patients with compar-
able levels of ethnic diversity, diagnostic profiles and
co-morbidity [18,19]. Furthermore, both FES are closely
connected with clinics (PRIME in New Haven and
CEDAR at Boston) directed by Co-Investigators on this
grant that are part of the NIH-funded North American
Prodrome Longitudinal Study (NAPLS). This is a con-
sortium of clinical research centers studying ways to
identify individuals who are at risk for an initial psych-
otic episode. Both sites have thus had a long history of
community engagement around early intervention and
experience with common measurement procedures.
While the prodrome clinics and FES at both sites have
acquired customary referral sources and interested local
stakeholders, neither have implemented the TIPS-style
ED strategies proposed here i.e. either by intensive public
education, intensive targeting of referral sources or oper-
ationalizing rapid access to their FES. Hence the early de-
tection approach in STEP-ED will deliver a qualitative,
rather than a merely quantitative change in the ED (STEP)
vs. no-ED (PREP
R) site. This will be confirmed by mea-
sures of publicity and outreach activities at both sites be-
fore and during the STEP-ED campaign.
Stakeholder engagement
Salient stakeholders are a robust element of this project.
Specifically, message development will include input from
the core audience of younger mental health consumers,
caregivers and professional groups. Relevant institutional
partners include the National Alliance for the Mentally Ill
Table 1 Components of STEP-ED campaign
A. Public education campaign (PEC) with messages targeting:
(i) patients; (ii) parents/caregivers and (iii) friends to empower them to
facilitate entry into care. Will include the following channels of
communication:
(1) Social media (e.g. Facebook, Twitter, YouTube)
(2) Mass media: including radio, (limited) TV, newspapers, mailings
(3) Interactive campaign website
(4) Posters on buses
(5) Promotional items
B. Professional outreach & detailing (POD) with distinct
strategies targeting:
(1) Educational settings (College counseling, School Based Health Clinics)
(2) Mental health services (Public and private, agency and solo practice)
(3) Primary care settings (Adult and Pediatric)
(4) Religious organizations
(5) Consumer organizations
(6) Judicial system
(7) Policy and Legislative actors
(8) Social Welfare Agencies
C. Rapid Access to STEP (RAS) including: A variety of performance improvement measures focused on reducing
time between referral and entry into treatment at the STEP clinic.
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Centers and Departments of Mental Health. Professional
organizations such as the Connecticut chapters of the
American Psychiatric Association, the American Academy
of Child and Adolescent Psychiatry and National Associ-
ation of School Psychologists have made specific commit-
ments to assist in dissemination of the campaign message
via newsletters or invitations to present at annual meet-
ings. Additionally, an extensive network of contacts devel-
oped by the PRIME and STEP clinics over several years
from invited presentations and consultations represents a
vital background of strong and credible support from the
multiple community health agencies and educational insti-
tutions within our catchment.
Measurement
Choice of measures
Measuring DUP Consensus on a valid measure of DUP
has been elusive. There are difficulties in reliably deter-
mining the onset of a private mental event and also
reasonable differences in opinion on what constitutes
meaningful offset, or when treatment can be considered
to have begun [50]. We will collect detailed onset data
for a variety of psychotic phenomena and treatment
events in order to allow comparison with other study co-
horts. For the purposes of planning our recruitment, we
chose to define onset of DUP per the threshold criteria for
positive or disorganized symptoms of psychosis in the
Symptom Onset Scale (SOS) [51]. The SOS was chosen
for several reasons: (a) it is comprehensive, rating the
severity and dating the onset of 16 general prodromal,
positive, negative, and disorganization symptoms, as well
as recording clinician, family, and patient global ratings of
onset of illness; (b) it has good reliability; [51] and (c) both
sites in New Haven and Boston have had considerable ex-
perience with this instrument over ≥5y e a r s .
With respect to offset, we conceptualize DUP1 as end-
ing on the date of initiation of antipsychotic medication
treatment targeting psychosis. Given evidence that these
symptoms can respond within a few days of antipsychotic
medication treatment, [52] we chose initiation over more
stringent criteria for adequacy of medication treatment
proposed by others (e.g. adequate dose with 75% adher-
ence for at least 4 weeks [53]). This will allow us to disen-
tangle timing from quality of treatment (in which one
might include the receipt of an adequate antipsychotic
trial). Assessors will collect an inventory of every medica-
tion prescribed to the patient, including dates and min-
imal adherence to help determine the offset of DUP1. We
define DUP2 as the date of admission to an FES (STEP/
PREP
R or other comparable services in the Boston area).
This approach allows us to evaluate the differential impact
of the campaign on various definitions of offset [53] and
subsequently, on 1 year outcomes.
Measuring the impact of ED on DUP Any attempt to
reduce, measure and evaluate the impact of DUP reduc-
tion within the complex U.S. healthcare environment
raises challenges for disentangling the effect of the ED
campaign from multiple, dynamic sources of variability
in DUP. One approach would be to rely on interventions
that focus on particular hypothesized mediating variables
(e.g. stigma) that can then be measured and mechanis-
tically tied to the desired outcomes. This would require
assumptions about which factors would be most relevant
to reduce DUP in any particular community that are un-
warranted given the current level of knowledge of such
factors. Indeed, while surveys or focus groups are intui-
tively appealing ways to elucidate these factors, the same
realities that result in prolonged DUPs makes access to
informative and representative samples of first-episode
patients, or their families, impractical. We will instead
deploy an adaptation of a previously successful approach
to DUP reduction (i.e. TIPS) while also collecting detailed
information about pathways to care across the two sites
that will improve knowledge of factors salient to DUP.
While it is possible that relative changes in these pathways
at the ED vs. non-ED site may be caused by unmeasured
factors that are unrelated to the campaign, the ambitious
goal of halving the log-transformed DUP is intended to
make it very unlikely that this could be achieved without a
meaningful change in these mediating pathways.
We will use an adapted version of the Pathways to
Care Interview [54] to gather systematic information (from
patients, caregivers and clinical records) about the source,
motivation, sequence and timing of help-seeking by pa-
tients and their families, the response offered by their first
contacts for help (whether at clinical, educational, or other
institutions), and the sequence and duration of subsequent
contacts until entry into STEP/PREP
R. The instrument has
been modified to assist evaluation of the campaign by
eliciting the sources of information that directed them
toward STEP/PREP
R. The data will allow assessment for
changes in both the ‘demand’ and ‘supply’ components
of DUP. Also, visual ‘route timelines’ along the modified
Goldberg-Huxley model (Figure 1) will be generated to
evaluate and respond to prominent sources of rapid ac-
cess or delay within the catchment.
Measuring the impact of DUP reduction on early
(1-year) outcomes The effect of ED on early outcomes
will be measured in the year following entry into treat-
ment. While significant symptomatic improvement has
already been demonstrated during this period for a ma-
jority of treated first-episode patients in U.S. settings, [8]
the impact of earlier engagement with an FES is hypothe-
sized to manifest in added gains in social and vocational
functioning. A composite outcome of ‘vocational engage-
ment’ defined as the proportion of patients who are in at
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the Global Functioning Social and Role Scales [55]. We
will also categorize patients’ vocational activity according
to Bureau of Labor Statistics definitions, to allow for
comparison with peers in local and national samples.
We will also account for patients who are not in the
labor force due to being a student or caregiver. Add-
itional broad quality of life measures will include the
Heinrichs-Carpenter Quality of Life Scale, [56] and the
Short Form Health Survey (SF 36) [57].
Psychiatric diagnoses will be informed by a baseline and
1 year SCID (Structured Clinical Interview for DSM-IV)
[58]. The Structured Interview for Prodromal Syndromes
(SIPS), Version 5.3, given at baseline, will provide a pre-
liminary assessment of whether the patient is at-risk for
psychosis or has crossed the threshold into psychosis. It
also provides additional data regarding onset dates for
putative prodromal symptoms. The Global Assessment of
Functioning from this measure adds a well-anchored,
population-appropriate scale of overall functioning and
will be repeated throughout the study. Symptoms will be
measured using the Positive and Negative Symptom Scale
(PANSS) [59] and the Calgary Depression Scale [60].
While violence resulting in injury to others is a rare out-
come in psychotic disorders, as many as a third of patients
will have committed a violent act before entering treat-
ment and prolonged DUP has been associated with acts of
serious violence [9]. The Modified Overt Aggression Scale
(MOAS) [61] will be used to assesses three types of self-
reported violence: physical aggression, verbal aggression
and property aggression. Suicidality will be assessed
with the Columbia Suicide Severity Scale (C-SSRS) [62].
Substance use will be monitored with the Alcohol Use
and Drug Use Scales [63], a Habits Inventory, and the
SCID. Data on services used and other societal costs
(e.g. criminal/legal, public assistance) will be obtained
with the Services Utilization and Resources Form for
Schizophrenia (SURF) [64]. The SURF is a multi-item
form that uses participants’ or caregivers’ report to
document comprehensively the number, type, and dur-
ation of health services and consumption of non-health
resources, such as criminal justice events and public as-
sistance. This form has been adapted for use with the
younger population in this study. The Premorbid Ad-
justment Scale (PAS) [65] will be acquired at baseline to
assess preexisting differences in functioning. A brief se-
lection of neuro- and social cognitive measures from
t h eM A T R I C Sb a t t e r yw i l lb eu s e d .
Evaluating the impact of ED within a year limits the
significant attrition bias that tends to accrue over longer
follow-up periods with this challenging population [66].
Indeed, one of the outcomes that are hopefully impacted
by ED will be the quality and duration of engagement
with care. The Service Engagement Scale [67] will help
assess the domains of availability, collaboration, nature
of help seeking and medication adherence.
Table 2 depicts assessment timeline. Further clinical
assessment (at STEP/PREP
R) will include routine phys-
ical and neurological examination with an initial work-
up for common ‘secondary’ causes of psychosis that will
include blood tests for a complete blood count, standard
electrolyte and hepatic panels, thyroid function and urine
toxicology and, when clinically indicated, testing for syph-
ilis and HIV and structural brain imaging.
Raters at each site will be trained using a set of common
vignettes developed from historical cases at each site. Reli-
ability assessment will focus on accurate measurement of
DUP and pathways to care. Regular consensus calls will
determine the team’s level of confidence (definite, prob-
able or possible) in psychosis onset date from the SOS
and offset date from the Prescription Medication Log.
These measures will be repeated at 1 month when confi-
dence in the initial estimate of DUP is only “possible” or
“probable”. Ongoing monitoring of inter-rater reliability,
as often as every three months for the key measures, will
help reduce drift among raters and between sites.
Statistical considerations
Choice of primary and secondary outcomes
The primary outcome of this study is DUP2. This is re-
lated to our primary aim of shortening time to entry into
Table 2 Research evaluation procedures and timeline
Months after enrollment in FES 0 6 12
SIPS x
SOS & Prescription Medication Log x*
Pathways to Care Interview x
SCID I, selected SCID II sections x x
Demographics, Medical History x
Neurocognitive & Social cognitive battery: x x x
1. premorbid IQ estimate- WRAT-4 reading (only at baseline)
2. processing speed: MATRICS symbol digit
3. verbal learning: MATRICS Hopkins verbal learning test
4. social cognition: MATRICS- MSCEIT
Habits inventory, AUS/DUS, Cannabis Scale x x x
PANSS, Calgary Depression x x x
Premorbid Adjustment Scale x
Global Functioning: Social and Role x x x
Service Utilization and Resources Form (modified) x x x
Service Engagement Scale (SES) x x
LUNSERS medication side effect scale x x x
GAF, Heinrichs QOL, SF-36 Health Survey x x x
Suicidality (C-SSRS), Aggression (MOAS) x x x
*repeated within one month if confidence in DUP estimate is “possible”
or “probable”.
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a more direct measure of the ‘demand’ contributors to
overall DUP, while the difference (DUP2-DUP1) related
more directly to ‘supply’ side contributors.
The secondary aim of this study is to determine if DUP
reduction results in improvements in clinical state at en-
rollment and improvements in treatment engagement and
functional outcomes above and beyond that afforded by
an FES. There is no evidence of a threshold at which DUP
becomes significantly more determinative of outcome
[68]. Analyses from different cohorts have suggested
that efforts be made to shorten DUP to <1 month [69]
or <3 months [70] but these differences likely result from
heterogeneity in the samples and nature of the outreach
efforts. Given this, we will not use an arbitrary threshold
to adjust for baseline DUP (that could post-hoc make our
FES’ look better or worse), but instead used linear re-
gression across the full range of baseline DUPs to inter-
rogate mediation effects on differential outcomes across
the 2 sites.
Sample size and power
Since there is no conventional closed-form to estimate
the statistical power for this type of design, we applied a
flexible method to simulate the power empirically [71].
1000 simulation datasets were generated by drawing ran-
dom examples based on the alternative hypothesis of the
design. The proposed analysis was then performed in
each simulated dataset. The empirical power is the frac-
tion of p values which are smaller than 0.05.
Extant measures of DUP are known to have a non-
normal distribution, and the natural log-transformation
will be used to estimate sample size. Our primary hy-
pothesis is that the ED campaign will effectively decrease
DUP at STEP vs. PREP (non-ED site). Based on historical
data from 2006–2013, the estimated geometric means and
standard deviations were 3.7±3.7 months (corresponding
to 1.3±1.3 in a natural log scale) for PREP and 5.0±
3.7 months (corresponding to 1.6±1.3 in natural-log
scale) for STEP. We project that DUP will remain within
the same range at PREP during years 2 through 4, but will
decrease from 1.6 to 0.8 in the natural log scale at STEP
(ED site). This effect size corresponds to a 55% decrease
in the geometric mean DUP (months), and is comparable
to the TIPS I study (1997–2000, n = 281) that reduced
DUP to a median of 5 weeks [range, 0–1196 weeks] from
16 weeks [range, 0–966 weeks]. To power our study, we
include historical DUP data from PREP (n=44) and STEP
(n-99) into the pre-campaign group. We plan to enroll 22
more subjects at PREP and 34 more at STEP during the
first year (pre-campaign, as the baseline control for each
site), as well as 66 participating at PREP and 102 partici-
pants at STEP during years 2, 3, and 4 (post-campaign).
With the sample sizes of 66 (44 plus 22) at PREP and 133
(99 plus 34) subjects at STEP during the pre-campaign
period, and 66 at PREP and 102 at STEP during the post
campaign period, we will have 81% empirical power to de-
tect a difference of 0.8 in the change of log-DUP from pre
to post period between two sites at 0.05 alpha level.
Analysis plan
Patient characteristics will be compared between sites and
between periods. The primary analysis will be two-way
analysis of variance (two-way ANOVA) that includes two
categorical explanatory variables both with two levels:
period (“pre campaign” & “post campaign”) and site
(“STEP” & “PREP
R”). The combination of historical data
since 2006 and the first year outcome data for each site
will serve as the reference to estimate change in DUP (in
natural log scale) at each site. The primary hypothesis is
the ED campaign will result in greater decline in DUP at
STEP compared to PREP
R.T h ei n t e r a c t i o no fp e r i o da n d
site will be used to test this hypothesis. This test is of pri-
mary interest for our study, although linear contrasts will
be also conducted to compare between-site differences for
the pre- and post-campaign periods. A significant inter-
action effect between period and site will disconfirm the
null hypothesis and show that the outcome varies between
pre and post campaign periods depending upon the em-
ployment of early detection. We do not anticipate signifi-
cant main effects, but a significant study period effect
would indicate a pre vs. post study difference on average
across sites and a significant site effect would indicate that
one site had a greater DUP on average across study pe-
riods. In addition, adjusted analyses will be performed
with inclusion of covariates. Potential confounders such as
participants’ age, gender, race/ethnicity will be included in
the adjusted analyses.
A supportive analysis will investigate any effect of time
by including the fixed effect of year. Other secondary
analyses will include modeling of the observed percen-
tiles of DUP (e.g., quartiles in months) using quantile
regression, with the same main and interaction effects
as in the approach of primary analysis. Overall, we
chose our primary analysis to reflect an investigation of
perhaps the most clinically meaningful change in DUP
(decrease from pre period at STEP), whereas our sup-
portive analysis will give us more insight into how early
detection affects DUP across the range of DUPs ob-
served during the pre period.
Other analyses related to our secondary aim, will inter-
rogate whether and to what extent DUP reductions pre-
dicted improvements in clinical presentation, treatment
engagement and measures of symptomatic and func-
tional recovery.
Statistical significance will be established in all analyses
at alpha =0.05 and analyses will be performed using SAS
9.3 (Cary, NC).
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This study will adapt and test an approach to early detec-
tion that will employ several innovations in design, deliv-
ery and measurement highlighted below:
1. Innovating with the end in mind. The project
leverages existing public-academic collaborations to
implement a catchment-based approach to early
detection. This will allow evaluation of scalability
across similar sectors of the state and country for a
given value (outcomes/cost) [72]. STEP and PREP
R
are each integrated, within 2 of 50 nationwide State
Mental Health Agencies that constitute a de facto
national mental health system, reaching into nearly
every community in the country and serving patients
in the public sector, with serious mental illnesses.
While states differ considerably in the level and
mechanisms of funding, the presence of a 50+year
old infrastructure in the public sector with experience
in the care of severe and persistent mental illnesses
provides a natural framework within which to build a
national approach [18].
2. The use of social marketing has not to our
knowledge been previously attempted for improving
access to mental health care. This involves the
adaptation of commercial marketing approaches
towards behavior change that will be applied in the
service of public health goals. A variety of
stakeholders (parents, friends, professionals and
young patients) whose behavior this campaign will
seek to influence, will be engaged to develop and
test messages. Online analytic tools will be used to
track the uptake of messages and refine the
campaign and represents an advance over
traditional, static mass media messaging.
Furthermore, the leveraging of social media to target
adolescents and young adults will we hope deliver
more effective and age appropriate ways to engage a
population well known to resist entry into mental
healthcare systems which have been traditionally
oriented towards older, chronically ill patients. The
details of the resulting campaign will be described in
a forthcoming paper.
3. The project takes a deliberately ‘interventionist’
stance to assessing local pathways to care i.e. the
mounting of a campaign targeting presumed sources
of DUP is expected to reveal more actionable
information about these sources of delay and other
salient features of local pathways. This is in contrast
to surveying the community for barriers that may
not reliably predict those that are actually operative
in determining DUP. This is in keeping with our
model of DUP as resulting from a more dynamic
interplay between demand and supply contributors.
Pathways to care for each patient will be systematically
assessed using structured interviews of patients, care-
givers and clinicians and reviews of clinical documents.
Barriers of greatest salience (magnitude and/or malle-
ability) are presumed to vary across the heterogeneous
U.S. landscape. Our use of a measure that will allow gen-
eration of locally detailed maps will allow us to describe
and respond to the sometimes exquisitely local barriers
that characterize U.S. pathways to care. While TIPS fo-
cused on enhancing mental health literacy on the one
hand and making FES more rapidly responsive to refer-
rals on the other, it took for granted the existing institu-
tional structures that defined the pathways within which
patients and caregivers sought care. By taking a more ag-
nostic stance on pathways and assessing in detail events
and actors in both the ‘demand’ and ‘supply’ sides of DUP
we will be able to provide information on how these indi-
viduals and organizations perform as a network of care
and suggest sustainable ways to change them and sustain
DUP reductions beyond the life of the campaign.
In summary, testing an empirically based DUP reduc-
tion strategy (Primary Aim) is a logical next step for
both FES programs (STEP & PREP
R) as we seek effective
ways to hasten access to our established and effective
services. Also, demonstrating the added value of success-
ful early detection (ED) to an existing FES (STEP) in a
controlled manner (Secondary Aim) will inform models
of how best to resource and implement a comprehensive
approach to secondary prevention for psychotic disor-
ders in the U.S. Given this project’s integration within a
public-academic collaboration, the results will be primed
for national dissemination.
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